DNA-Thioguanine (DNA-TG) Is a Promising Novel Method to Predict Adverse Events to Thiopurine in Inflammatory Bowel Disease

Ahmed Bayoumy Bayoumy, Ludovicus Jozef Johannes Derijks, Nanne Klaas Hendrik de Boer

Research output: Contribution to Journal › Article › Academic › peer-review

Original languageEnglish
Pages (from-to)612-613
Number of pages2
JournalInflammatory Bowel Diseases
Volume31
Issue number2
DOIs
Publication statusPublished - 10 Feb 2025

Funding

A.B. has nothing to declare. N.K.d.B. has served as a speaker for AbbVie and MSD and has served as a consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS, and Takeda. L.D. has served as a speaker for AbbVie, Celltrion, Janssen-Cilag and Takeda and has developed continuing education materials for Ferring. All outside the submitted work.

FundersFunder number
TEVA Pharma BV
Takeda Pharmaceutical Company

    Access to Document

    Persistent URL (handle)

    Cite this